Novo Nordisk A S
NVO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000353278
No open-market purchases or sales by Novo Nordisk A S insiders were filed in the last 90 days; 1,355 institutions reported holding it in 13F filings for Q2 2026, worth $15.7B in total; superinvestors Markel Group and Maverick Capital hold it.
Other share classesNONOF
Holders of 5% or more of NVO
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Novo Nordisk A S, largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Novo Nordisk A S on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on Novo Nordisk A S, newest first.
No Schedule 13D or 13G filings on Novo Nordisk A S are on file.
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Novo Nordisk A S shares.
No Form 144 notices for Novo Nordisk A S are on file.